鲑鱼降钙素对老年糖尿病患者骨质疏松的临床治疗效果观察

目的探讨鲑鱼降钙素对老年糖尿病患者骨质疏松的临床治疗疗效。方法对我院收治的140例老年糖尿病并骨质疏松患者随机分为治疗组和对照组,治疗组的患者给予鲑鱼降钙素进行治疗,对照组的患者给予钙尔奇治疗。结果对照组患者治疗疗效的总有效率为54.3%,治疗组患者临床治疗疗效的总有效率为91.4%,两组治疗方法在临床疗效上存在显著的差异性（P〈0.05）。结论鲑鱼降钙素应用于老年糖尿病患者骨质疏松临床治疗中取得的疗效显著,能够有效缓解患者的骨质疼痛,值得在临床上广泛应用和推广。     

鲑鱼降钙素注射液治疗原发性骨质疏松的疗效观察

目的探讨鲑鱼降钙素注射液治疗原发性骨质疏松的临床疗效。方法将本院112例原发性骨质疏松患者随机分为单纯钙剂治疗组（对照组）和鲑鱼降钙素注射液联合钙剂治疗组（观察组）,每组各56例,观察两组患者的临床疗效。结果观察组患者治疗总有效率为94.6%,显著高于对照组患者的75.0%,组间差异有统计学意义（P〈0.05）,治疗过程中两组患者均未出现明显不良反应。结论鲑鱼降钙素注射液治疗原发性骨质疏松临床疗效较为可靠,值得临床进一步推广使用。     

鲑鱼降钙素喷鼻剂治疗原发性骨质疏松症疼痛的88例分析

目的探讨鲑鱼降钙素喷鼻剂治疗骨质疏松疼痛的临床疗效。方法88例骨质疏松症患者应用鲑鱼降钙素喷鼻剂治疗2个疗程,观察疼痛缓解情况及生活改善情况。结果治疗2个疗程,疼痛缓解率76％,生活质量改善有效率为83％。结论鲑鱼降钙素喷鼻剂能明显缓解骨质疏松性疼痛,改善患者生活质量。     

鲑鱼降钙素治疗老年骨质疏松症的临床研究

目的讨论鲑鱼降钙素治疗老年骨质疏松症的临床疗效。方法对100例老年骨质疏松患者采用鲑鱼降钙素联合应用钙剂治疗,并设立对照组单独应用钙剂治疗,观察骨密度改变及疼痛症状缓解程度。结果3个月后随访,骨密度明显增强,骨质疏松引起疼痛症状明显缓解。与对照组比较差异有统计学意义。结论鲑鱼降钙素治疗老年性骨质疏松症,具有不良反应小,使用方便,能有效缓解骨痛,提高患者的骨量。     

鲑鱼降钙素治疗原发性骨质疏松症的疗效观察

目的：观察鲑鱼降钙素在治疗原发性骨质疏松症中的疗效。方法：106例骨质疏松患者随机分成研究组和对照组,研究组采用鲑鱼降钙素联合钙剂治疗,对照组单纯使用钙剂。结果：研究组患者经过治疗后骨密度显著增加（P〈0.01）;疼痛缓解率达79.63%;生活能力明显提高,与对照组相比均有显著差异（P〈0.01）。结论：鲑鱼降钙素在治疗原发骨质疏松症中疗效良好。     

鲑鱼降钙素治疗骨质疏松性椎体骨折疼痛的疗效观察

目的 观察鲑鱼降钙素治疗老年骨质疏松性椎体骨折疼痛的临床疗效.方法 2004年1月～2006年10月,采用鲑鱼降钙素(50IU,im,qd)治疗51例老年骨质疏松性椎体骨折患者,采用VAS评分法评价治疗前后的疼痛缓解情况.结果 鲑鱼降钙素联合钙剂治疗2周后的患者自发性背痛、前屈后伸、翻身痛以及负重痛的疼痛指数分别减轻了(3.9±1.22)、(4.4±1.38)、(3.7±1.02)、(4.2±1.35)分,均较治疗前有显著改善(P＜0.05),不良反应发生率为13.72%,无严重并发症发生.结论 鲑鱼降钙素短期内能有效缓解老年骨质疏松性椎体骨折疼痛.     

鲑鱼降钙素治疗老年骨质疏松性椎体骨折疼痛的疗效观察

目的:观察鲑鱼降钙素治疗老年骨质疏松性椎体骨折疼痛的临床疗效.方法:102例老年骨质疏松性椎体骨折患者分成两组,实验组采用鲑鱼降钙素联合钙尔奇D治疗51例,对照组采用钙尔奇D治疗51例.采用VAS评分分析治疗前后的疼痛缓解情况.结果:实验组鲑鱼降钙素联合钙剂治疗2周后的患者自发性背痛、前屈后伸痛、翻身痛以及负重痛的疼痛指数分别减轻了(3.9±1.22),(4.4±1.38),(3.7±1.02),(4.2±1.35)分,均较治疗前有显著改善(P<0.05),不良反应发生率为13.72%.结论:鲑鱼降钙素短期内能有效缓解老年骨质疏松性椎体骨折疼痛.     

鲑鱼降钙素在老年糖尿病并发骨质疏松患者中的疗效分析

目的探讨鲑鱼降钙素在老年糖尿病并发骨质疏松患者中的疗效。方法我院治疗的老年糖尿病并发骨质疏松患者45例,均给予鲑鱼降钙素肌内注射治疗。观察患者的临床疗效以及治疗前后的血尿生化检查、骨密度和疼痛的改善情况。结果 45例患者的总有效率为97.78%;治疗后各种疼痛较治疗前均有明显改善;L2、L3、L4、股骨颈、股骨粗隆以及华氏三角区各点的骨密度较治疗前均有明显的改善;BGP以及Ca/Cr较治疗前有明显的改善,但血清Ca治疗前后比较,差异无统计学意义;均无明显的过敏性不良反应。结论鲑鱼降钙素与钙剂联合使用治疗糖尿病并发骨质疏松具有疗效确切、不良反应少的特点,值得临床推广使用。     

降钙素治疗骨质疏松疼痛的疗效观察及机理分析

目的：探讨鲑鱼降钙素治疗骨质疏松疼痛的临床疗效并分析其机理。方法１０２例骨质疏松骨痛患应用鲑鱼降钙素治疗４周,分别于治疗前,治疗１、２、３、４周及治疗后２周观察疼痛强度、疼痛缓解度。结果治疗４周、疼痛完全缓解率５２．９％,明显缓解率３０．４％,中度缓解率１１．８％;镇痛总有效率９５．１％,显效率８３．３％,有效率１１．８％。结论骨质疏松疼痛是多因素所致单因素改善无法根本缓解疼痛。降钙素既可能以体     

鲑鱼降钙素鼻喷剂治疗绝经后骨质疏松患者骨密度及骨转换指标的变化探讨

目的：探讨鲑鱼降钙素鼻喷剂对绝经后骨质疏松的临床治疗效果及骨密度和骨转换指标的变化。方法：对我院收治的80例绝经后骨质疏松患者的资料进行分析，根据治疗方案分为对照组和实验组，对照组采用钙剂治疗，实验组使用鲑鱼降钙素鼻喷剂治疗，比较两组疗效及骨密度和骨转换指标的变化。结果：实验组治疗后L1、L2、L3、L4、股骨颈、Wards区、大转子、桡骨远端，显著高于对照组（P<0.05）；实验组治疗后血ALP、血BGP、尿Ca/Cr、尿HOP/Cr、尿DPD/Cr，显著低于对照组（P<0.05）；两组血Ca和血P指标无显著差异（P>0.05）。结论：绝经后骨质疏松采用鲑鱼降钙素鼻喷剂治疗的效果理想，能抑制骨吸收，增加骨量，值得临床推广。     

Design and evaluation of poly(DL-lactic-co-glycolic acid) nanocomposite particles containing salmon calcitonin for inhalation

Salmon calcitonin, for the treatment of calcium homeostasis and bone remodeling, was used as a model peptide drug and adsorbed on the surface of biodegradable polymeric poly(dl-lactic-co-glycolic acid) (PLGA) nanospheres. Subsequently, the nanospheres were treated using lyophilizer and loaded onto inhalable carrier using Mechanofusion to obtain nanocomposite particles suitable for inhalation. The physicochemical properties and in vitro inhalation properties of the nanocomposite particles were investigated. The pulmonary distribution and pharmacological effect were also evaluated in male Wistar rats. The results showed that the drug loading efficiency of salmon calcitonin on PLGA nanospheres were exceeding 96% (w/w). Inhalation efficiency of the lyophilized PLGA nanospheres was largely improved after they were loaded on the surface of inhalable carrier. Over 50% (w/w) of the lyophilized PLGA nanospheres could be deposited in the alveoli section after intratracheal administration to male Wistar rats, while a rapid elimination rate of the lyophilized nanospheres from the lung was found in pulmonary distribution study. The in vivo pharmacological study showed that the nanocomposite particles exhibited superior hypocalcemic action over salmon calcitonion solution and the lyophilized nanospheres. It suggested that the Mechanofusion(TM) technique can impart improved inhalation properties to the lyophilized nanospheres for pulmonary delivery of therapeutic peptide drugs.     

己烯雌酚对去卵巢大鼠骨代谢影响的定量研究

目的：观察己烯雌酚对去卵巢大鼠骨质疏松的作用及机制。方法：用４．５ｍｇ·Ｌ－１的己烯雌酚按５ｍｌ·ｋｇ－１·ｄ－１ｉｇ，每周６次。１２ｗｋ后，用半自动图象数字化分析仪对大鼠胫骨近段不脱钙骨片进行骨计量学分析。结果和结论：己烯雌酚能明显抑制去卵巢引起的骨高转换，使治疗组的骨量明显高于去卵巢组（％Ｔｂ．Ａｒ＋１２２％），但未能完全防止去卵巢引起的小梁骨丢失（与对照组比较：％Ｔｂ．Ａｒ－２８％）。     

骨质疏松症的药物治疗现状

目的;介绍骨质疏松症的药物治疗现状。方法：参考国内外文献,从药理作用、临床疗效和不良反应及发展前景等方面综述VD、降钙素、雌激素、双膦酸盐盐、氟化物、甲状旁腺激素、VK2、伊普拉芬、钙剂和骨生长因子制剂等骨质疏松症治疗药物。结果与结论：上述十类药物对骨质疏松症治疗都有效,其作用机制及疗程长短尚待深入研究。     

低频脉冲电磁场联合鲑鱼降钙素治疗原发性骨质疏松症

目的观察低频脉冲电磁场联合鲑鱼降钙素治疗对原发性骨质疏松症的疗效。方法将119例患者分为两组,一组采用低频脉冲电磁场联合鲑鱼降钙素治疗,一组采用鲑鱼降钙素治疗。结果 4周后疼痛缓解出现差异,低频脉冲电磁场联合鲑鱼降钙素治疗优于鲑鱼降钙素治疗组,6个月后,有67例复查骨密度,治疗组平均骨密度增长10.29%,两组比较差异有统计学意义。结论低频脉冲电磁场联合鲑鱼降钙素治疗原发性骨质疏松症,二者有明显协同作用,对缓解骨痛,提高骨密度,优于单一治疗。     

潜水减压病性骨梗死的影像学表现

目的探讨潜水减压病性骨梗死的影像学表现。方法 19例患者23个部位均行X线、CT、MR检查,病变累及股骨颈、股骨粗隆、肱骨上端、胫骨下端。结果骨梗死早、中期X线片、CT表现为阴性和局部骨质疏松及斑点状钙化;MRI表现为中央T1WI为中等或略低信号,边缘为迂曲清楚的线状低信号带,T2WI为中央等略高而边缘高信号带,边缘呈典型的地图样改变,反映了骨梗死内的反应性新骨形成、纤维化、出血和骨髓水肿。晚期X线及CT呈不规则状骨质硬化,MRI T1WI及T2WI示梗死区中央及边缘均为低信号,这意味坏死组织被肉芽组织和纤维组织替代,及营养不良性钙化和骨化。结论 MRI是诊断早期骨梗死的最有效的方法,而中晚期骨梗死在X线平片、CT及MRI上均有特征性表现,三者结合可以提高诊断率。     

去卵巢大鼠骨代谢变化与雌激素替代治疗效果

目的：观察绝经与骨质疏松的关系和绝经后以雌激素替代治疗的效果。方法：采取切除３月龄ＳＤ大鼠双侧卵巢方法，７ｗｋ后发现大鼠松质骨和密质骨骨量减少、骨小梁稀疏、骨皮质变薄、骨髓腔扩大等明显骨质疏松病理改变，同时伴有体重增加、肾上腺和子宫萎缩、血磷下降等现象。骨细胞水平研究表明去势后大鼠骨吸收增强，骨形成减弱，骨代谢处于负平衡状态。去卵巢同时灌胃给予３０μｇ·ｋｇ－１·ｄ－１雌激素（己烯雌酚）进行替代治疗。结果：去卵巢大鼠的骨量（尤其是密质骨骨量）丢失明显减少，骨组织显微结构病变和临床表现有较大改善。结论：雌激素替代治疗具有较好的防治骨质疏松效果。     

Salmon calcitonin in the treatment of bone metastases

The effects of salmon calcitonin administered 100 IU i.m. daily for 30 consecutive days were evaluated in patients with painful bone metastasis secondary to different types of solid cancer. The results were compared with placebo-receiving patients. In the 22 patients treated with calcitonin a significant reduction ( p less than 0.001) was observed in the severity of bone pain. Significant reductions were also encountered in the serum alkaline phosphatase (p less than 0.02) and urinary hydroxyproline excretion values (p less than 0.05) in calcitonin-treated patients, indicating an inhibition of bone destruction. It is concluded that salmon calcitonin has an important place in the treatment of patients with metastatic bone lesions both as a potent analgesic and as an effective inhibitor of bone destruction.     

中西药结合治疗绝经后骨质疏松临床疗效观察

目的观察中西药结合治疗绝经后骨质疏松的临床疗效。方法227例确诊患者随机分为3组：中西药组、中药组和西药组。各组给予不同的治疗药物,为期6个月。检测骨代谢相关指标及性激素水平。结果各组治疗后BMD、血清骨代谢相关指标和性激素水平均有所上升,尿中骨代谢相关指标均有所下降。其中中西药组治疗前后各指标值最大,差异具有显著性意义（P〈0.05）。结论中西药结合治疗绝经后骨质疏松疗效确切。     

鲑鱼降钙素联合仙灵骨葆、骨化三醇对预防骨折内固定术后骨质疏松性骨痛的疗效观察

目的观察鲑鱼降钙素联合仙灵骨葆、骨化三醇对预防骨折内固定术后骨质疏松性骨痛的疗效。方法将206例骨折内固定术后患者随机分为治疗组69例、对照Ⅰ组69例和对照Ⅱ组68例,治疗组术后予以鼻喷鲑鱼降钙素,同时口服仙灵骨葆和骨化三醇治疗;对照Ⅰ组仅予以鼻喷鲑鱼降钙素治疗;对照Ⅱ组予以口服仙灵骨葆联合骨化三醇治疗。3组均以30d为1个疗程,连续使用3个疗程。评定3组骨痛性质及程度,测定血钙、血磷,记录药物不良反应发生情况。结果治疗组骨痛改善总有效率为92.8%,高于对照Ⅰ组的71.0%、对照Ⅱ组的64.7%,差异均有统计学意义(P<0.05)。3组血磷和血钙水平治疗前、后及组间比较差异均无统计学意义(P>0.05)。3组不良反应发生率两两比较差异均无统计学意义(P>0.05)。结论鲑鱼降钙素联合仙灵骨葆、骨化三醇对预防骨折内固定术后骨质疏松性疼痛具有确切的疗效,是一种安全、有效的治疗方法。     

Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.

Salmon calcitonin, a polypeptide hormone secreted by the parafollicular C cells of the thyroid gland, lowers serum calcium levels by decreasing bone resorption and renal tubular calcium reabsorption. An analgesic action, possibly mediated via beta-endorphins, is also evident. In the past, parenteral formulations of salmon calcitonin have been used in the management of metabolic bone disorders, but their routine use has been limited by the inconvenience of this route of administration and by poor tolerability. The development of an intranasal preparation of salmon calcitonin will provide a more convenient means of administering the drug. In clinical trials published to date intranasal salmon calcitonin has been effective and well tolerated in small numbers of recently postmenopausal women at risk of developing osteoporosis, and in patients with established osteoporosis, Paget's disease, or osteoporosis secondary to corticosteroid usage, multiple myeloma or ovariectomy. For periods of up to 2 years the drug reduces bone resorption and improves bone architecture, relieves pain and increases functional status. Further research is needed to confirm longer term efficacy (in particular, effects on fracture rate), optimal dosage schedules and the role of intermittent and combination treatment regimens.